Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention
Abstract Background Incidence of pulmonary aspergillosis is rising worldwide, owing to an increased population of immunocompromised patients. Notable potential of the pulmonary route has been witnessed in antifungal delivery due to distinct advantages of direct lung targeting and first-pass evasion....
Main Authors: | Ranjot Kaur, Sarah R. Dennison, Andrea J. Burrow, Shivaprakash M. Rudramurthy, Rajan Swami, Varun Gorki, O. P. Katare, Anupama Kaushik, Bhupinder Singh, Kamalinder K. Singh |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Journal of Nanobiotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12951-020-00731-1 |
Similar Items
-
Orbital Aspergillosis: Voriconazole – The New Standard Treatment
by: Derek H. Ohlstein, et al.
Published: (2012-02-01) -
Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
by: Sacha Sarfati, et al.
Published: (2022-07-01) -
Successful treatment of multiple intracerebral aspergillosis with voriconazole alone in an Egyptian diabetic patient with autoimmune hemolytic anemia
by: Hamdy Ibrahim, et al.
Published: (2023-10-01) -
Invasive aspergillosis: Is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
by: G Schnetzler, et al.
Published: (2006-10-01) -
Voriconazole-Induced Hepatotoxicity in a Patient with Pulmonary Aspergillosis: A Case Report
by: Gu L, et al.
Published: (2023-08-01)